C12N 2795/14041
Use of virus, viral particle or viral elements as a vector
C12N2795/14041 (Use of virus, viral particle or viral elements as a vector) appears on 16 US grants and 22 published applications in this corpus.
Search patents in C12N- Granted patents
- 16
- Published applications
- 22
- Assignees
- 11
- Inventors
- 20
- Latest grant
- 1 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 2 | 0 |
| 2002 | 3 | 1 |
| 2003 | 4 | 1 |
| 2004 | 0 | 3 |
| 2005 | 1 | 1 |
| 2006 | 1 | 3 |
| 2007 | 0 | 2 |
| 2008 | 0 | 1 |
| 2009 | 1 | 1 |
| 2010 | 1 | 0 |
| 2011 | 1 | 2 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 1 | 0 |
| 2025 | 1 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2795/14043Viral genome or elements thereof as genetic vectorIndexing code15
- C12N 2795/14042Virus or viral particle as vehicleIndexing code1
- C12N 2795/14044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
- C12N 2795/14045Special targeting system for viral vectorsIndexing code0
Recent patents
- Targeted genome modification using circular single-stranded DNA1 Jul 2025US 12,344,858 B2Full Circles Therapeutics, Inc.
- Scalable biotechnological production of DNA single strand molecules of defined sequence and length27 Feb 2024US 11,913,050 B2Technische Universität München
- Dual expression vector system for antibody expression in bacterial and mammalian cells15 Mar 2011US 7,906,327 B2MacroGenics, Inc.
- Methods and compositions for polypeptide engineering17 Aug 2010US 7,776,598 B2Maxygen, Inc.
- Methods and compositions for polypeptide engineering19 May 2009US 7,534,564 B2Maxygen, Inc.
- Components for genomic editing13 Aug 2026US 2026/0234657 A1Kano Therapeutics Inc.
- Targeted genome modification using circular single-stranded dna28 May 2026US 2026/0146261 A1Full Circles Therapeutics, Inc.
- A clinical isolated avirulent strain protects against wildtype virulent clostridioides difficile infection23 Oct 2025US 2025/0325599 A1The University of Chicago
- M13 bacteriophage with a high cysteine content and genetically engineerable hydrogels28 Sep 2023US 2023/0304025 A1Massachusetts Institute of Technology
- Targeted genome modification using circular single-stranded dna4 Nov 2021US 2021/0340571 A1Stellate Biotherapeutics, Inc.
Most cited
By later US patents
- Methods and compositions for polypeptide engineering338US 6,586,182 B1Maxygen, Inc. · 2003
- Methods and compositions for polypeptide engineering217US 6,303,344 B1Maxygen, Inc. · 2001
- Methods and compositions for polypeptide engineering206US 6,335,160 B12002
- Methods and compositions for polypeptide engineering188US 6,946,296 B2Maxygen, Inc. · 2005
- Methods and compositions for polypeptide engineering180US 6,319,713 B1Maxygen, Inc. · 2001